07:41 AM EDT, 09/04/2025 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Thursday that it was informed by the US Food and Drug Administration that an advisory committee meeting is not required for its new drug application for Anaphylm sublingual epinephrine film to treat severe allergic reactions, including anaphylaxis.

The target action date for Anaphylm remains on Jan. 31, 2026, the company said.

The company's shares were up 5% in recent Thursday premarket activity.